JPRN-UMIN000007736已完成未知
Phase II trial of Dasatinib monotherapy for Philadelphia positive acute lymphoblastic leukemia in the Elderly - DASPAL-E
Study group of DASPAL-E0 个研究点目标入组 25 人开始时间: 2012年4月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. active double cancer 2. uncontrollable complication 3. past history of TKI/chemotherapy 4. physicians' decision
研究者
相似试验
招募中
2 期
Phase II clinical trial of low dose dasatinib in patients with resistant or intolerant chronic myeloid leukemia who are treated with low lose imatinibChronic myeloid leukemia patients in chronic phase who are refractory or resistant to low dose imatinib therapy.JPRN-UMIN000003499Kanto CML Study Group30
已完成
2 期
Phase II clinical trial of dasatinib in newly diagnosed chronic phase chronic myelogenous leukemianewly diagnosed chronic myelogenous leukemia in chronic phaseJPRN-UMIN000006346Ph leukemia trial Group50
进行中（未招募）
1 期
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutatioCarcinoma, Non-small cell lungMedDRA version: 14.1 Level: LLT Classification code 10007284 Term: Carcinoma System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864EUCTR2011-003128-11-GBBristol-Myers Squibb International Corporation19
进行中（未招募）
不适用
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutatioCarcinoma, Non-small cell lungMedDRA version: 14.1Level: LLTClassification code 10007284Term: CarcinomaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2011-003128-11-DEBristol-Myers Squibb International Corporation73
进行中（未招募）
不适用
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutatioEUCTR2011-003128-11-PLBristol-Myers Squibb International Corporation73